person · Reporting owner

Fong Peter

Disclosed activity across 1 company

Tapewire entity: 32080
SEC CIK: 0002062181

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627	Director	June 18, 2026	July 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ROCKET PHARMACEUTICALS, INC.

Report date June 18, 2026 · Filed July 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	76,195	Reported balance After 2026-06-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 76,195 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18	Direct	64,860	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.

F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 18, 2026 Filed Jul 7, 2026 00:00 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantStock Option (Right to Buy) · Derivative	64,860	$0.00 Strike: $3.35	$0.00	Disclosure SEC source: 0001140361-26-027680 · form4.xml · derivative · entry 2 Fong Peter · CIK 0002062181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,860 Underlying: Common Stock · 64,860 shares Expires 2036-06-18 F2 · derivative.exercise_date: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. Read SEC document
June 18, 2026 Filed Jul 7, 2026 00:00 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	22,862	$0.00	$0.00	Disclosure SEC source: 0001140361-26-027680 · form4.xml · nonDerivative · entry 1 Fong Peter · CIK 0002062181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,195 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. F2 · kind: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. F2 · price: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. Read SEC document
September 24, 2025 Filed Oct 4, 2025 00:33 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001140361-25-037275 · form4.xml · nonDerivative · entry 2 Fong Peter · CIK 0002062181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,333 F2 · kind: Represents RSUs that will vest in equal monthly installments over a three-year period following September 23, 2025. F2 · shares: Represents RSUs that will vest in equal monthly installments over a three-year period following September 23, 2025. F2 · price: Represents RSUs that will vest in equal monthly installments over a three-year period following September 23, 2025. Read SEC document
September 24, 2025 Filed Oct 4, 2025 00:33 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	23,333	$0.00	$0.00	Disclosure SEC source: 0001140361-25-037275 · form4.xml · nonDerivative · entry 1 Fong Peter · CIK 0002062181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,333 F1 · kind: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on September 24, 2026. F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on September 24, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on September 24, 2026. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.